On August 21, 2024, Director J Singleton sold 5,700 shares of Viking Therapeutics Inc (VKTX, Financial) as reported in a recent SEC Filing. Following this transaction, the insider now owns 9,500 shares of the company.
Viking Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. The company's lead clinical program, VK5211, is in development for the treatment of patients recovering from non-elective hip fracture surgery.
According to the filing, the shares were sold at a price of $69.72, valuing the transaction at approximately $397,404. This sale is part of a broader trend observed over the past year, where the insider has sold a total of 42,486 shares and made no purchases.
The broader insider transaction history for Viking Therapeutics Inc shows a pattern of selling activities, with 17 insider sells and no insider buys over the past year. This could be of interest to investors looking for patterns in insider behaviors.
Shares of Viking Therapeutics Inc were trading at $69.72 on the day of the transaction, giving the company a market cap of approximately $7.13 billion. The company's valuation metrics, such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, are also accessible for further insights.
The following insider trend image provides a visual representation of the recent insider transactions:
For more detailed valuation, investors might consider looking at the GF Value of Viking Therapeutics Inc to assess whether the stock is currently undervalued or overvalued.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
